14.20
-0.10 (-0.70%)
| Penutupan Terdahulu | 14.30 |
| Buka | 14.33 |
| Jumlah Dagangan | 1,339,015 |
| Purata Dagangan (3B) | 2,056,415 |
| Modal Pasaran | 1,662,039,040 |
| Harga / Jualan (P/S) | 11.85 |
| Harga / Buku (P/B) | 10.88 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -140.97% |
| Margin Operasi (TTM) | -87.29% |
| EPS Cair (TTM) | -1.67 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 17.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 132.90% |
| Nisbah Semasa (MRQ) | 2.46 |
| Aliran Tunai Operasi (OCF TTM) | -167.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.38 M |
| Pulangan Atas Aset (ROA TTM) | -31.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -192.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Arcutis Biotherapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 0.5 |
| Purata | -0.70 |
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.15% |
| % Dimiliki oleh Institusi | 113.65% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 20.00 (Mizuho, 40.85%) | Beli |
| Median | 19.00 (33.80%) | |
| Rendah | 18.00 (Needham, 26.76%) | Beli |
| Purata | 19.00 (33.80%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 13.26 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Jan 2025 | 19.00 (33.80%) | Beli | 13.63 |
| 30 Dec 2024 | 19.00 (33.80%) | Beli | 14.20 | |
| Mizuho | 07 Jan 2025 | 20.00 (40.85%) | Beli | 15.76 |
| Needham | 07 Nov 2024 | 18.00 (26.76%) | Beli | 10.40 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| WELGUS HOWARD G. | - | 14.56 | -10,000 | -145,600 |
| Jumlah Keseluruhan Kuantiti Bersih | -10,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -145,600 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 14.56 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WELGUS HOWARD G. | Pengarah | 02 Jan 2025 | Jual automatik (-) | 10,000 | 14.56 | 145,600 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |